TVTX NASDAQ
Travere Therapeutics, Inc.
1W: -2.7%
1M: -17.4%
3M: -8.4%
YTD: +28.7%
1Y: +81.3%
3Y: +603.7%
5Y: +107.1%
$50.88
+0.91 (+1.82%)
Pre-Market: $51.55 (+0.67, +1.33%)
Weekly Expected Move ±6.1%
$44
$47
$50
$53
$56
Credit Risk of going bust: higher than 56% of companies Debt: 11.4% of company value Bonds: $101.5M held by 42 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.80 (down 98%), Travere Therapeutics, Inc. would be worth roughly what it owes.
Total debt $616.9M against a stock market value of $4.80B.
Distance to default 4.60 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $307.6M (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' -2.95. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.80 (down 98%), Travere Therapeutics, Inc. would be worth roughly what it owes.
Total debt $616.9M against a stock market value of $4.80B.
Distance to default 4.60 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $307.6M (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' -2.95. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
Travere Therapeutics, Inc. $TVTX Position Lifted by Assenagon Asset Management S.A.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Target Price of $69.50
These healthcare stocks stand out with A+ growth grades
Travere Therapeutics, Inc. $TVTX Stock Position Lowered by NewEdge Advisors LLC
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell?
Travere Therapeutics appoints Bradley Campbell as CEO, replacing Eric Dube
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $2,337,750.00 in Stock
Travere Therapeutics (NASDAQ:TVTX) CAO Sells $335,023.75 in Stock
Bank of America Corp DE Invests $259.53 Million in Travere Therapeutics, Inc. $TVTX
Hsbc Holdings PLC Sells 176,242 Shares of Travere Therapeutics, Inc. $TVTX
Artia Global Partners LP Buys New Shares in Travere Therapeutics, Inc. $TVTX
Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript
Empowered Funds LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX
Travere signals potential for more than $3B in peak annual FILSPARI sales as FSGS launch exceeds expectations
Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
SA Asks: What are the most attractive biotech stocks right now?
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
Travere (TVTX) Q1 2026 Earnings Transcript
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere Therapeutics Non-GAAP EPS of $0.05 beats by $0.10, revenue of $124.5M misses by $12.27M
Travere (TVTX) Q2 2025 Earnings Transcript
Travere (TVTX) Q4 2025 Earnings Transcript
Here are the major earnings after the close Monday
Organon & Co is the best performing healthcare stock in April
Earnings Scheduled For May 4, 2026
Jennison Associates LLC Trims Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
Calamos Advisors LLC Buys Shares of 72,305 Travere Therapeutics, Inc. $TVTX
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Assetmark Inc. Acquires New Position in Travere Therapeutics, Inc. $TVTX
AstraZeneca's Ultomiris Meets Goal in Rare Kidney Disease Study
Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started?
Travere Therapeutics (NASDAQ:TVTX) CAO Sells $902,595.39 in Stock
Travere Therapeutics (NASDAQ:TVTX) Director Sells $1,352,247.50 in Stock
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Rating of “Moderate Buy” from Brokerages
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4% After Insider Selling
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients
Roy Baynes Sells 10,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
Aberdeen Group plc Trims Holdings in Travere Therapeutics, Inc. $TVTX
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $300,000.00 in Stock
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 60,000 Shares
Travere Therapeutics, Inc. $TVTX Shares Purchased by Assenagon Asset Management S.A.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of “Moderate Buy” from Analysts
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
166,000 Shares in Travere Therapeutics, Inc. $TVTX Purchased by Apis Capital Advisors LLC
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of “Moderate Buy” by Analysts
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 5.4% – Here’s What Happened
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins
Travere Therapeutics Targets April FSGS FILSPARI Decision as IgAN Sales Accelerate, HCU Trial Restarts
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy?
Travere Therapeutics (TVTX) Projected to Post Quarterly Earnings on Thursday
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm
Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 8,135 Shares
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 51,865 Shares of Stock
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
Emerald Advisers LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX
Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA
Why Travere Therapeutics Stock Got Trounced on Tuesday
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
SHAREHOLDER ALERT: Travere Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Should Contact The Firm
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
Options Bears Eye Plummeting Biotech Stock
Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Travere Therapeutics Provides Corporate Update and 2026 Outlook
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 15,000 Shares
Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 7,402 Shares of Stock
Investors Purchase High Volume of Travere Therapeutics Call Options (NASDAQ:TVTX)
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Federated Hermes Inc. Sells 145,110 Shares of Travere Therapeutics, Inc. $TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Franklin Resources Inc. Boosts Stock Holdings in Travere Therapeutics, Inc. $TVTX
Capital Fund Management S.A. Acquires Shares of 101,406 Travere Therapeutics, Inc. $TVTX